NCT00050414 - A Study of Trabectedin in Patients With Advanced Ovarian Cancer | Biotech Hunter

Enrollment

147

Participants

Timeline

Start Date

October 31, 2002

Study Completion Date

September 30, 2005

Conditions

Ovarian NeoplasmsEndocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, Female

Interventions

DRUG

Trabectedin

Trabectedin 0.58 mg/m2, administered as a 3-hour intravenous infusion, Days 1, 8, and 15 every 28 days for up to approximately 3 years in the absence of disease progression.

DRUG

Dexamethasone

Dexamethasone 10 mg administered intravenously 30 minutes prior to each trabectedin infusion.